Biophysical characterization of drug-resistant mutants of fibroblast growth factor receptor 1
出版年份 2016 全文链接
标题
Biophysical characterization of drug-resistant mutants of fibroblast growth factor receptor 1
作者
关键词
-
出版物
GENES TO CELLS
Volume 21, Issue 10, Pages 1049-1058
出版商
Wiley
发表日期
2016-08-25
DOI
10.1111/gtc.12405
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Nuclear magnetic resonance analysis of the conformational state of cancer mutant of fibroblast growth factor receptor 1 tyrosine kinase domain
- (2016) Yoshihiro Kobashigawa et al. GENES TO CELLS
- Illuminating the Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance for the FGFR1 Gatekeeper Mutation: The Achilles’ Heel of Targeted Therapy
- (2015) Christal D. Sohl et al. ACS Chemical Biology
- Structural analysis of the mechanism of phosphorylation of a critical autoregulatory tyrosine residue in FGFR1 kinase domain
- (2015) Yoshihiro Kobashigawa et al. GENES TO CELLS
- Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase
- (2015) Tobias Klein et al. Nature Communications
- The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study
- (2015) Tom D. Bunney et al. EBioMedicine
- The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors
- (2015) Sara A Byron et al. NEOPLASIA
- DFG-out Mode of Inhibition by an Irreversible Type-1 Inhibitor Capable of Overcoming Gate-Keeper Mutations in FGF Receptors
- (2014) Zhifeng Huang et al. ACS Chemical Biology
- Structural Analysis of the Human Fibroblast Growth Factor Receptor 4 Kinase
- (2014) E. Lesca et al. JOURNAL OF MOLECULAR BIOLOGY
- Structural Insights into FGFR Kinase Isoform Selectivity: Diverse Binding Modes of AZD4547 and Ponatinib in Complex with FGFR1 and FGFR4
- (2014) Julie A. Tucker et al. STRUCTURE
- Receptor Tyrosine Kinases: Legacy of the First Two Decades
- (2014) J. Schlessinger Cold Spring Harbor Perspectives in Biology
- Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate Cancer Progression
- (2012) S. Feng et al. CLINICAL CANCER RESEARCH
- Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor
- (2012) S Yoshikawa et al. ONCOGENE
- Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance
- (2012) V Chell et al. ONCOGENE
- The rise and fall of gatekeeper mutations? TheBCR-ABL1T315I paradigm
- (2011) Don L. Gibbons et al. CANCER
- Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen
- (2011) Sen Zhang et al. Chemical Biology & Drug Design
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance
- (2010) Tianjun Zhou et al. Chemical Biology & Drug Design
- Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression
- (2009) G Chen et al. BRITISH JOURNAL OF CANCER
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Activation of tyrosine kinases by mutation of the gatekeeper threonine
- (2008) Mohammad Azam et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started